Safety and efficacy of sildenafil citrate in reversal of cerebral vasospasm: A feasibility study

Surgical Neurology International

Volumn 3, Issue 1, 2012, Pages

  Mukherjee, Kanchan K ^a   Singh, Shrawan K ^a   Khosla, Virender K ^a   Mohindra, Sandeep ^a   Salunke, Pravin ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Sildenafil citrate; subarachnoid hemorrhage; vasospasm

Indexed keywords

ELECTROLYTE; SILDENAFIL;

ARTICLE; BLURRED VISION; BRAIN VASOSPASM; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; DOPPLER ECHOGRAPHY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROLYTE BLOOD LEVEL; FEASIBILITY STUDY; FLUSHING; HEADACHE; HEMATOMA; HUMAN; HYDROCEPHALUS; HYPOTENSION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SIDE EFFECT; VISUAL DISORDER;

EID: 84865596341     PISSN: None     EISSN: 21527806     Source Type: Journal    
DOI: 10.4103/2152-7806.92164     Document Type: Article

References (17)

1. Atalay B, Caner H, Cekinmez M, Ozen O, Celasun B, Altinors N. Systemic administration of phosphodiesterase V inhibitor, sildenafil citrate, for attenuation of cerebral vasospasm after experimental subarachnoid hemorrhage. Neurosurgery 2006;59:1102-7.
2. Bischoff E. Pharmacology of phosphodiesterase inhibitor. In: Broderick G, editor. Oral Pharmacotherapy for Male Sexual Dysfunction: A Guide to Clinical Management. 1 st ed. New Jersey: Humana Press Inc.; 2005. p. 47.
3. Bozgeyik Z, Berilgen S, Ozdemir H, Tekatas A, Ogur E. Evaluation of the effects of sildenafil citrate (viagra) on vertebral artery blood flow in patients with vertebro-basilar insufficiency. Korean J Radiol 2008;9:477-80.
4. Carson C 3rd. Sildenafil: First in the therapeutic class of phosphodiesterase type 5 inhibitors. In: Carson C 3 rd, Kirby R, Goldstein I, Wyllie M, editors. Text Book of Erectile Dysfunction. 2 nd ed. New York: Informa Healthcare; 2009. p. 231-5.
5. Dorsch N. Therapeutic approaches to vasospasm in subarachnoid hemorrhage. Curr Opin Crit Care 2002;8:128-33.
6. Dorsch NW. A review of cerebral vasospasm in aneurismal subarachnoid hemorrhage. Part II: Management. J Clin Neurosci 1994;1:78-92.
7. Fazan R Jr, Huber DA, Silva CA, Dias da Silva VJ, Salgado MC, Salgado HC. Sildenafil acts on the central nervous system increasing sympathetic activity. J Appl Physiol 2008;104:1683-9.
8. Hansen-Schwartz J. Cerebral vasospasm. A consideration of the various cellular mechanism involved in the pathophysiology. Neurocrit Care 2004;1:235-46.
9. Kaneria MV, Pagar S, Samant H, Yeole S, Patil S. Subarachnoid haemorrhage: Possibly caused by the illegitimate use of sildenafil citrate. Assoc Physicians India 2008;56:809-11.
10. Kumar R, Pathak A, Mathuriya SN, Khandelwal N. Intraventricular sodium nitroprusside therapy: A future promise for refractory subarachnoid hemorrhage induced vasospasm. Neurol India 2003;51:197-202.
11. Lee KH. "Triple-H" therapy for cerebral vasospasm following subarachnoid hemorrhage. Neurocrit Care 2006;4:68-76.
12. Liu JK, Couldwell WT. Intra-arterial papaverine infusions for the treatment of cerebral vasospasm induced by aneurysmal subarachnoid hemorrhage. Neurocrit Care 2005;2:124-32.
13. Lorberboym M, Mena I, Wainstein J, Boaz M, Lampl Y. The effect of sildenafil citrate (Viagra) on cerebral blood flow in patients with cerebrovascular risk factors. Acta Neurol Scand 2010;121:370-6.
14. Meyer FB. Calcium antagonists and vasospasm. Neurosurg Clin N Am 1990;1:367-76.
15. Pathak A, Mathuriya SN, Khandelwal N, Verma K. Intermittent low dose intrathecal sodium nitroprusside therapy for treatment of symptomatic aneurismal SAH-induced vasospasm. Br J Neurosurg 2003;17:306-10.
16. Reneerkens OA, Rutten K, Steinbusch HW, Blokland A, Prickaerts J. Selective phosphodiesterase inhibitors: A promising target for cognition enhancement. Psychopharmacology (Berl) 2009;202:419-43.
17. Rosenkranz S, Caglayan E, Erdmann E. Novel indications for phosphodiesterase type 5 inhibitors. Med Klin (Munich) 2007;15:617-30.